<DOC>
	<DOCNO>NCT02260440</DOCNO>
	<brief_summary>This open label , single-arm , Phase 2 trial evaluate anti-tumor activity , safety , tolerability Pembrolizumab combination azacitidine subject chemo-refractory mCRC without standard treatment option Dosage regimen study period - Pembrolizumab give 200 mg every 21 day . - Azacitidine give 100 mg daily subcutaneous injection day 1-5 every 21 day . The first assessment tumor response perform cycle 3 ( 9 week ) , thereafter approximately every 9 week , every 3 cycle therapy . The modified RECIST 1.1 use establish disease response progression . All patient evaluate graded adverse event accord NCI Common Terminology Adverse Events , version 4.0 ( NCI-CTCAE ) .</brief_summary>
	<brief_title>A Phase 2 Study Pembrolizumab ( MK-3475 ) Combination With Azacitidine Subjects With Chemo-refractory Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Be willing able provide write informed consent/assent trial . 2 . Be 18 year age old day signing inform consent . 3 . The diagnosis mCRC base histologic cytologic confirmation . 4 . Have mCRC previously treat currently approve standard therapy . 5 . Have measurable disease base RECIST 1.1 . 6 . At least 1 tumor site must amenable core needle biopsy may site disease use measure antitumor response . Patient must agree mandatory biopsy . 7 . Have performance status 0 1 ECOG Performance Scale . 8 . Demonstrate adequate organ function , screen lab perform within 14 day treatment initiation . 9 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 10 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 11 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 1 . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 3 . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 4 . Has prior chemotherapy , target small molecule therapy , radiation therapy within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . 5 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy.. 6 . Has extensive metastatic tumor burden liver serum albumin &lt; 3.0 g/dL . 7 . Has know renal tubular acidosis serum bicarbonate &lt; 20 mEq/L . 8 . Has know hypersensitivity azacitidine mannitol . 9 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . 10 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . 11 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 12 . Has active infection require systemic therapy . 13 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 14 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 15 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 16 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . 17 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 18 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>